Advertising
BUY
A public vehicle in the quasi-private business. Takes advantage of opportunities in the marketplace, hold them until they mature, and then sells them. They continue churning money. Incredibly successful at it. Can continue to hold the company. They pay out a percentage of their profit bases. Switched from a LP to a regular listed company. Continues to pay fairly large distributions.
investment companies / funds
DON'T BUY
A broad company with many types of drugs. Laws in the US stipulates that after spending millions of dollar for franchises, the drug will go off patent in time. Pharmaceuticals have been doing this for a long time.
biotechnology / pharmaceutical
DON'T BUY
Broadly, pharmaceuticals and healthcare space is not providing a ton of opportunity. Trading at reasonable valuations with 3 divisions. Consumer business is in trouble because more people are going towards generics. Pharma business hasn't seen much tailwind from covid vaccines.
biotechnology / pharmaceutical
COMMENT
He's been saying that the seasonal period starting today will be a rocky one. It was as stocks sank today. Also, bearish sentiment hasn't peaked since the Dotcom period. Also stocks pull back, you may need to buy into that decline. September/October seasonality is consistent. This year, supply chain constraints, the Delta effect and other worries are factors.
Unknown
COMMENT
They report Monday. Excellent managers. He wants them to talk about supply shortages and home demand. Lennar is important to retail, banking and the hybrid work from home economy.
REAL ESTATE
COMMENT
It reports Tuesday. It has been hit with a ton of negative commentary. Will they say anything to give us a reason to buy? We'll see.
Transportation
BUY
It reports Tuesday. It's become the bellwhether of tech stocks. The stock has been on fire, because business is booming; their products are essential to e-commerce. He loves their suite of products.
computer software / processing